Triptorelin doesn't avert early ovarian failure in lymphoma

November 7, 2012
Triptorelin doesn't avert early ovarian failure in lymphoma
Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure, according to a study published online Nov. 5 in the Journal of Clinical Oncology.

(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure (POF), according to a study published online Nov. 5 in the Journal of Clinical Oncology.

Isabelle Demeestere, M.D., Ph.D., of the Université Libre de Bruxelles in Belgium, and colleagues conducted a one-year follow-up of a multicenter, randomized, prospective trial involving 84 patients with lymphoma, aged 18 to 45 years of age, to assess the efficacy of the GnRHa triptorelin plus norethisterone versus norethisterone alone in preventing chemotherapy-induced ovarian failure.

The researchers found that after six months of follow-up there was no difference between the groups in the mean follicle stimulating hormone values. After one year, there was no significant difference in the rate of POF between the GnRHa and control groups (20 and 19 percent, respectively). Ovarian function was completely restored for more than half the patients in each group, and higher anti-Müllerian hormone values were seen in the GnRHa group versus the . were similar between the groups, except for metrorrhagia, which was seen more often in the GnRHa group.

"In conclusion, this prospective study involving patients with did not provide evidence that GnRHa is effective in preventing POF," the authors write. "However, it suggests a long-term benefit of GnRHa on fertility of patients who spontaneously experience restoration of ovarian function. Until long-term results confirm the benefit of GnRHa to improve future fertility, the treatment should not be administered to prevent POF apart from in experimental protocols."

One author disclosed financial ties to Ipsen.

Explore further: Socioeconomic class and smoking linked to premature menopause

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Socioeconomic class and smoking linked to premature menopause

July 6, 2011

Women from the lowest social class are almost three times as likely to have premature ovarian failure as those from the highest social class, a researcher told the annual conference of the European Society of Human Reproduction ...

Drug cocktail boosts ovarian cancer survival time

June 2, 2012

A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

Life span of ovarian grafts longer than expected

June 28, 2012

Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas ...

Watch-and-wait OK in low-tumor burden follicular lymphoma

September 26, 2012

(HealthDay)—An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.